Fig. 1From: Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpointCoronaVac vaccine-induced SARS-CoV-2 neutralizing antibody response and corresponding seroprevalences after two primary doses plus a third dose of CoronaVac vaccine. A Fitted SARS-CoV-2 antibody titer dynamics. B Fitted seroprevalence, using a protective threshold of 33Back to article page